SCHEMBL3733652

SCHEMBL3733652

CC(C)(C)OC(=O)N1CC(S)CC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
KDM4E B2RXH2 2/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
NR1H2 P55055 1/20 0.37
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM1A O60341 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
POLB P06746 1/20 0.34
HSD11B1 P28845 1/20 0.33
DTYMK P23919 1/20 0.33
HPGD P15428 1/20 0.33
AR P10275 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24364276 0.84 MEN1 (0.42) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL18878053 0.81 CHRM2 (0.53) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL433051 0.81 CHRM2 (0.41) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL3744207 0.81 CHRM2 (0.41) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL3744023 0.81 CHRM2 (0.41) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL6442167 0.81 CHRM2 (0.53) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL21452961 0.81 CHRM2 (0.41) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL3738809 0.81 CHRM2 (0.53) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL20187325 0.79 CHRM2 (0.40) MEN1KMT2ACHRM2CHRM1CHRM3
SCHEMBL26416181 0.79 CHRM2 (0.40) MEN1KMT2ACHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242285-B2 N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 US disclosed
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 US disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 US disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 MEN1 2455/4885KMT2A 1777/4885CHRM2 1573/4885
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof TERT, CBR1, TELO2 MEN1 2455/4885KMT2A 1777/4885CHRM2 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.